2020.May.29
OBI has filed application of Phase I/II human clinical studies for passive immunotherapeutic monoclonal antibody OBI-888 to TFDA
Date of occurrence of the event: May 29, 2020 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: Not applicable Cause of occurrence: OBI has filed the application of phase I/II human clinical studies for passive immunotherapeutic monoclonal antibody OBI-888 to TFDA. OBI-888 has […]
This article is password protected.
To view the content, please enter your password in the field below